Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 


Print Friendly Page

Protocol No. UW17017

Principal Investigator Cho, Steven

Phase II

Age Group Adult

Scope Local

Sponsor Type Institutional

Title PSMA Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging in Gynecological Cancers

Objective The purpose of this research is to test contrast-enhanced MRI and F-DCFPYL PET imaging. We want to see how clear and accurate images of the normal uterus, ovaries and fallopian tubes are when using this kind of PET/MRI scan. We also want to see if this PET/MRI scan can identify uterine and ovarian cancer.

Treatment F-DCFPYL PSMA is an investigational tracer. "Investigational" means that F-DCFPYL PSMA is not approved by the FDA and can only be used in research. This tracer can help identify gynecological (uterine and ovarian) cancers.

Description One study visit is required at the Wisconsin Institutes for Medical Research (WIMR) building. This visit will last approximately 3 hours.The F-DCFPYL PSMA will be injected through an IV that will be placed in your arm. You will then be positioned in the PET/MR scanner. During the scan, an MRI contrast agent and a small dose of glucagon will be injected in the IV in your arm.

Key Eligibility
  • Women with suspected gynecological cancer (test population)
  • Women with no suspected gynecological cancer (control population)
  • No contraindications for MR or PET imaging
  • Greater than or equal to 18 years of age
  • Scheduled to undergo a hysterectomy and salpingo-oophorectomy
  • Women that are pregnant or breast-feeding are excluded
  • Women with severe kidney dysfunction are excluded
  • Women with concurrent or previous non-gynecologic malignancy, other than treated skin cancer are excluded

Applicable Disease Sites Ovary; Uterus

Therapies Involved Other

Drugs Involved 18F-DCFPyL

Status Open

Participating Institutions UW Hospital and Clinics; UWCCC 1 South Park